 GAITHERSBURG, Md., Feb. 17, 2021 GLOBE NEWSWIRE -- NexImmune, Inc. Nasdaq: NEXI, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the bodys own T cells to generate a specific, potent and durable immune response, today announced the closing of its previously announced upsized initial public offering of 7,441,650 shares of its common stock at a price to the public of 17.00 per share, which includes the exercise in full by the underwriters of their option to purchase 970,650 additional shares. Including the option exercise, the gross proceeds to NexImmune from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately 126.5 million. 